[The predictive value of the anti-cardiolipin antibody test for malignant tumors].
To determine the predictive value of the IgG anti-cardiolipin antibody test for malignant tumor, two groups of the patients of Kurume and Kyushu University Hospitals were examined by quantitative enzyme linked immunoadsorbent assay (ELISA) for their serum anti-cardiolipin antibodies. With the first group of the patients consisting of a mixture of benign diseases and malignant tumors, the antibody was positive at 57% (39/72). With the second, malignant tumor group, 38% (19/50) was positive for the antibody. When examined for the specificity of the antibodies by a binding inhibition assay, it was shown that the antibodies in the tumor patients were less specific to cardiolipin: antibodies to cardiolipin in tumor patients were blocked by the specific antigen, cardiolipin, in a lesser degree than those in the control syphilis patients, and highly cross-reacted with 2 related phospholipids, i.e., phosphatidyl glycerol and phosphatidic acid. These findings obtained in this study suggest that ELISA for cardiolipin has the value for the tumor diagnosis, supplementing already established assays.
Makidono
R
R
Department of Immunology, Kurume University School of Medicine.
Jingu
K
K
D000906:Antibodies / Q000032:analysis*; D000918:Antibody Specificity; D014408:Biomarkers, Tumor / Q000097:blood*; D002308:Cardiolipins / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000097:blood*; D011379:Prognosis
D000906:Antibodies; D014408:Biomarkers, Tumor; D002308:Cardiolipins